Compass pathways stock forecast.

Apr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).COMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.

Jul 2, 2023 · COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast. At close: 04:00PM EST. 6.06 0.00 (0.00%) After hours: 07:09PM EST. Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from ...

Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.

Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.Web

CMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...

8 Wall Street research analysts have issued 1-year target prices for Compass' shares. Their COMP share price targets range from $2.25 to $5.00. On average, they expect the company's stock price to reach $3.39 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.On average, Wall Street analysts predict. that Compass's share price could reach $3.29 by Nov 21, 2024. The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43.Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... 2 พ.ย. 2566 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...On another note, COMPASS Pathways has 4 warning signs (and 2 which make us uncomfortable) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...Compass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat …COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.WebCOMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...

According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...

An in-depth look at the leading psychedelic stocks in the U.S stock market this year. Here’s what you need to know. ... Compass Pathways (NASDAQ:CMPS) $350.9 million Developing one psilocybin ...Jul 5, 2023 · (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ... Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebCompass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.13 มี.ค. 2566 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass …WebZacks forecast a loss of 55 cents per share. The company had zero revenue, as its main product, COMP360, is still in trials. ... Compass Pathways stock is in an IPO base with a 47.39 buy point.May 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9. Nov 13, 2021 · A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...

Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.

COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018

Apr 26, 2021 · Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ... COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ... Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy.Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...WebWe are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.WebThe consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...WebCOMPASS Pathways ’s (CMPS) stock price is $6.1 and COMPASS Pathways ’s (CMPS) 100-day simple moving average is 7.59, creating a Sell signal. COMPASS Pathways ’s ( CMPS ) stock price is $6.1 and COMPASS Pathways ’s ( CMPS ) 200-day simple moving average is 8.13 , creating a Sell signal. The current Compass Pathways PLC [ CMPS] share price is $6.45. The Score for CMPS is 52, which is 4% above its historic median score of 50, and infers lower risk than normal. CMPS is currently trading in the 50-60% percentile range relative to its …WebAbout CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.COMPASS Pathways (CMPS) Stock Forecast & Price Target $5.93 -0.05 (-0.84%) (As of 11/29/2023 ET) Compare Today's Range $5.84 $6.25 50-Day Range …NasdaqGS:CMPS Earnings and Revenue Growth April 12th 2021. COMPASS Pathways is not owned by hedge funds. Our data shows that ATAI Life Sciences AG is the largest shareholder with 22% of shares ...Instagram:https://instagram. nlr etfsmall cap companies to invest inproshares boilgle63s CMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) what is the best broker for mt5apples earnings report Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy. amam stock forecast Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...